Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Lynparza Gets First Mover Advantage In BRCA-Positive Breast Cancer

AstraZeneca and Merck & Co hope to advance Lynparza quickly in prostate and pancreatic cancers after getting first mover advantage in metastatic breast cancer.

Approvals Commercial Business Strategies

Allergan, Shire Battle In Dry Eye As Generics Advance

Market Snapshot: Shire is pushing Xiidra hard to take market share away from Allergan's well established Restasis, but the pending arrival of a generic Restasis throws a curveball into the whole category.

Ophthalmic Market Intelligence Business Strategies

Putting Innovation In The Spotlight

The Clinical and Research Excellence (CARE) Awards are Informa Pharma Intelligence's way of honoring the R&D accomplishments across the biopharmaceutical industry. Nominations are free and open through Jan. 19.

Clinical Trials Commercial Innovation
Advertisement


 Recent Tweets from Scrip


 

Commercial Explore this Topic

Roxadustat To Overtake Epogen In Treating Anemia In CKD By 2021

The market for the treatment of anemia in chronic kidney disease will see Epogen eroded by biosimilars before the overall segment finally returns to growth following the launch of HIF-PHI inhibitor roxadustat, according to Datamonitor Healthcare's latest forecast.

Renal Market Intelligence Biosimilars

CSL Looks Beyond Organic Growth To External Innovation

CSL Ltd.'s sales grew 15% in its last fiscal year and are expected to grow about 8% in FY 2018, but the Australia-based company is looking beyond its plasma protein expertise to outside innovation to help boost future revenue.

Business Strategies Companies Deals

Scrip Company Of The Year Celgene In Rude Health Despite Hiccups

Celgene, which continues to plough back a very high proportion revenues into R&D, remains the preferred partner of choice for biotechs who hope to bring the next wave of innovative products to the market, Kevin Loth, VP of corporate affairs and policy in Europe tells Scrip.

Commercial Business Strategies

WuXi Biologics To Be ‘World’s No.1’ Biologics Maker

WuXi Biologics is aiming high to become the world’s biggest biologics manufacturer within five years after seeing strong confidence from capital markets in its growth potential and a boost from its new biologics manufacturing facility. The Chinese company plans on more investment in early 2018 to prepare for an expected biologics surge in China, its chief executive tells Scrip.

Biologics Business Strategies

Forty Seven's IO Antibody Attracts Two Big Pharma Partners

Forty Seven Inc. has signed immuno-oncology deals with Merck of Germany and Roche that will see the launch of several combination studies for their PD-L1 inhibitors and Forty Seven's promising investigational CD47 antibody.

ImmunoOncology Deals

Cipla Revs Up In US, Newer Markets To Cushion Against Volatility

US scale-up plans, cost optimization and a deeper push in certain other markets to garner volumes and as a buffer against volatility were some of the key strategies discussed by Cipla’s CEO at the recent J.P. Morgan Healthcare Conference in San Francisco.

Commercial Strategy

J.P. Morgan Notebook Day 4: CRISPR's Not Worried; Theratechnologies' HIV Niche; And Is Moderna's IPO Coming Soon?

Daily round-up of news and notes from the 2018 J.P. Morgan Healthcare Conference: Alder's Options for CGRP drug; CRISPR's not worried about Cas9 controversy; Theratechnologies seeks more HIV niche products; Moderna is shaping up to have a big 2018; TG Therapeutics and Immunomedics milestones ahead.

Business Strategies Clinical Trials

Reflections From J.P. Morgan: Challenges As Always And Reasons For Optimism

Biopharma investors were underwhelmed by the deal-making news, but innovation, corporate tax reform and a relatively positive outlook on drug pricing left attendees at the J.P. Morgan Healthcare Conference with the sense that good things are in store for pharma in 2018.

Business Strategies Pricing Debate

Policy & Regulation Explore this Topic

Oral Testosterone Therapies Face Clinical Practice Difficulties, Advisory Panels Suggest

FDA's advisory committee voted down Lipocine's Tlando and Clarus' Jatenzo based on concerns about off-label use, but if they do reach the market, Tlando's lack of titration could pose problems for physicians, while both drugs could raise difficulties with the types of tubing used to test testosterone concentrations.

Advisory Committees Regulation Safety

All Systems Go as Roche MS Drug Ocrevus Secures EU Okay At Last

Now that the European Commission has finally given the go-ahead to Ocrevus, regarded by multiple sclerosis specialists as a game changer especially for the primary progressive form of the disease, observers will be watching to see what pricing strategy Roche adopts.

Approvals Neurology

Reflections From J.P. Morgan: Challenges As Always And Reasons For Optimism

Biopharma investors were underwhelmed by the deal-making news, but innovation, corporate tax reform and a relatively positive outlook on drug pricing left attendees at the J.P. Morgan Healthcare Conference with the sense that good things are in store for pharma in 2018.

Business Strategies Pricing Debate

Arbitrating Pharma Disputes On The Rise – Planning Ahead Makes Sense

Pharmaceutical companies risk coming up against complex and high value disputes in their everyday dealings and operations, and arbitration is increasingly being used to resolve these disputes. Lawyers Chris Parker and Elizabeth Reeves discuss the kinds of disputes pharmaceutical companies face, why international arbitration is well-suited to resolving such disputes, and what companies can do to plan ahead.

Legal Issues International

Research & Development Explore this Topic

In Dry Eye, A Variety Of Mechanisms Pursue Established Therapies

Market Snapshot: Kala's Phase III nanoparticle along with Aldeyra's aldehyde trap drug and Ocugen's brimonidine/steroid combo, both in Phase II, are among the candidates pursuing Restasis and Xiidra.

Ophthalmic Market Intelligence Clinical Trials

Vaccitech Will Seek Partners For Its Universal Flu Vaccine

Vaccitech's potential universal flu vaccine based on prime-boost technology is in early clinical trials in the UK, with partners likely to be sought for later-stage clinical studies; the company has just raised £20m in a Series A round from private investors that included Google's VC arm, GV, and Sequoia China.

Vaccines Financing

Pipeline Watch: Phase III Readouts For Eptinezumab, KPI-121 And Omidenepag Isopropyl

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Approvals Pipeline Watch

Tech Transfer Roundup: Mustang, Juno Advance Efforts With Immuno-Oncology

While Mustang was acquiring CAR-T intellectual property from Harvard and Juno licensed gamma-secretase inhibitor IP from OncoTracker and Fred Hutchinson for use with its CAR-Ts, Ocugen and Tamid licensed gene therapy research for ophthalmic uses.

Deals Platform Technologies
UsernamePublicRestriction

Register

Advertisement